Neuroprotective multifunctional iron chelators: From redox-sensitive process to novel therapeutic opportunities

Antioxidants and Redox Signaling

Volumn 13, Issue 6, 2010, Pages 919-949

  Weinreb, Orly ^a   Amit, Tamar ^a   Mandel, Silvia ^a   Kupershmidt, Lana ^a   Youdim, Moussa B H ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 5 (3,4,5 TRIMETHOXYBENZAMIDO)DECAHYDROISOQUINOLINE; 2,2' BIPYRIDINE; BENZOIC ACID DERIVATIVE; CLIOQUINOL; DEFEROXAMINE; EPIGALLOCATECHIN GALLATE; ETHYL 3,4 DIMETHYLBENZOATE; FLAVONOID; GALANGIN; HYDROXYL RADICAL; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IRON CHELATING AGENT; PHENOL DERIVATIVE; PROCOLLAGEN PROLINE 2 OXOGLUTARATE 4 DIOXYGENASE; QUERCETIN; TM 6008; UNCLASSIFIED DRUG; HYPOXIA INDUCIBLE FACTOR 1; NEUROPROTECTIVE AGENT;

DEGENERATIVE DISEASE; DRUG MECHANISM; FENTON REACTION; HUMAN; INFLAMMATION; IRON CHELATION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; ANIMAL; METABOLISM; NEURODEGENERATIVE DISEASES; OXIDATION REDUCTION REACTION;

ANIMALS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; IRON CHELATING AGENTS; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDATION-REDUCTION; OXIDATIVE STRESS;

EID: 77954947811     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2009.2929     Document Type: Review

References (365)

1. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li QX, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, and Bush AI. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59: 43-55, 2008
2. Akao Y, Maruyama W, Shimizu S, Yi H, Nakagawa Y, Shamoto-Nagai M, Youdim MBH, Tsujimoto Y, and Naoi M. Mitochondrial permeability transition mediates apo-ptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82: 913-923, 2002
3. Almli LM, Hamrick SE, Koshy AA, Tauber MG, and Ferriero DM. Multiple pathways of neuroprotection against oxidative stress and excitotoxic injury in immature primary hippocampal neurons. Brain Res Dev Brain Res 132: 121-129, 2001
4. Altamura S and Muckenthaler MU. Iron toxicity in diseases of aging: Alzheimer's disease, Parkinson's disease and atherosclerosis. J Alzheimers Dis 16: 879-895, 2009
5. Aminova LR, Chavez JC, Lee J, Ryu H, Kung A, Lamanna JC, and Ratan RR. Prosurvival and prodeath effects of hypoxia-inducible factor-1alpha stabilization in a murine hippocampal cell line. J Biol Chem 280: 3996-4003, 2005
6. Aminova LR, Siddiq A, and Ratan RR. Antioxidants, HIF prolyl hydroxylase inhibitors or short interfering RNAs to BNIP3 or PUMA, can prevent prodeath effects of the transcriptional activator, HIF-1alpha, in a mouse hippo-campal neuronal line. Antioxid Redox Signal 10: 1989-1998, 2008
7. Atamna H and Frey WH 2nd. A role for heme in Alzheimer's disease: heme binds amyloid beta and has altered metabolism. Proc Natl Acad Sci USA 101: 11153-11158, 2004
8. Atwood CS, Scarpa RC, Huang X, Moir RD, Jones WD, Fairlie DP, Tanzi RE, and Bush AI. Characterization of copper interactions with Alzheimer amyloid beta peptides: identification of an attomolar-affinity copper binding site on amyloid beta1-42. J Neurochem 75: 1219-1233., 2000
9. Avramovich-Tirosh Y, Amit T, Bar-Am O, Zheng H, Fridkin M, and Youdim MB. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer's disease. J Neurochem 100: 490-502, 2006
10. Avramovich-Tirosh Y, Bar-Am O, Amit T, Youdim MBH, and Weinreb O. Up-regulation of hypoxia-inducible factor (HIF)-1 alpha and HIF-regulated genes in cortical neurons by the novel anti-Alzheimer multifunctional iron chelator drugs. Curr Alzheimer Res, 2009 Dec 31. [Epub aheadofprint]
11. Avramovich-Tirosh Y, Reznichenko L, Mit T, Zheng H, Fridkin M, Weinreb O, Mandel S, and Youdim MB. Neu-rorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron-chelating-antioxidants, M-30 and green tea polyphenol, EGCG. Curr Alzheimer Res 4: 403-411, 2007
12. Baby SM, Roy A, Mokashi AM, and Lahiri S. Effects of hypoxia and intracellular iron chelation on hypoxia-inducible factor-1alpha and-1beta in the rat carotid body and glomus cells. Histochem Cell Biol 120: 343-352, 2003
13. Bandyopadhyay S, Huang X, Cho H, Greig NH, Youdim MB, and Rogers JT. Metal specificity of an iron-responsive element in Alzheimer's APP mRNA 5'untranslated region, tolerance of SH-SY5Y and H4 neural cells to desfer-rioxamine, clioquinol, VK-28, and a piperazine chelator. J Neural Transmission Suppl 71: 237-247, 2006
14. Banerjee A, Kunwar A, Mishra B, and Priyadarsini KI. Concentration dependent antioxidant=pro-oxidant activity of curcumin studies from AAPH induced hemolysis of RBCs. Chem Biol Interact 174: 134-139, 2008
15. Bar-Am O, Amit T, and Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and lados-tigil, respectively, exert neuroprotective properties in vitro. J Neurochem 103: 500-508, 2007
16. Bar-Am O, Weinreb O, Amit A, and Youdim MBH. The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline. J Neu-rochem 112: 1131-1137, 2010
17. Bar-Am O, Weinreb O, Amit T, and Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19: 1899-1901, 2005
18. Bartzokis G, Sultzer D, Cummings J, Holt LE, Hance DB, Henderson VW, and Mintz J. In vivo evaluation of brain iron in Alzheimer disease using magnetic resonance imaging. Arch Gen Psychiatry 57: 47-53, 2000
19. Ben-Shachar D, Eshel G, Finberg JP, and Youdim MB. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem 56: 1441-1444, 1991
20. Ben-Shachar D, Eshel G, Riederer P, and Youdim MBH. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Ann Neurol 32 (suppl): S105-S110, 1992
21. Ben-Shachar D, Kahana N, Kampel V, Warshawsky A, and Youdim MBH. Neuroprotection by a novel brain permeable iron chelator, VK-28, against 6-hydroxydopamine lesion in rats. Neuropharmacology 46: 254-263, 2004
22. Ben-Shachar D and Youdim MB. Intranigral iron injection induces behavioral and biochemical "parkinsonism" in rats. J Neurochem 57: 2133-2135, 1991
23. Benarroch EE. Brain iron homeostasis and neurodegener-ative disease. Neurology 72: 1436-1440, 2009
24. Berg D, Gerlach M, Youdim MB, Double KL, Zecca L, Riederer P, and Becker G. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem 79: 225-236, 2001
25. Bergeron M, Gidday JM, Yu AY, Semenza GL, Ferriero DM, and Sharp FR. Role of hypoxia-inducible factor-1 in hyp-oxia-induced ischemic tolerance in neonatal rat brain. Ann Neurol 48: 285-296, 2000
26. Bergeron M, Yu AY, Solway KE, Semenza GL, and Sharp FR. Induction of hypoxia-inducible factor-1 (HIF-1) and its target genes following focal ischaemia in rat brain. Eur J Neurosci 11: 4159-4170, 1999
27. Bernaudin M, Nedelec AS, Divoux D, MacKenzie ET, Petit E, and Schumann-Bard P. Normobaric hypoxia induces tolerance to focal permanent cerebral ischemia in association with an increased expression of hypoxia-inducible factor-1 and its target genes, erythropoietin and VEGF, in the adult mouse brain. J Cereb Blood Flow Metab 22: 393-403, 2002
28. Bernaudin M and Sharp FR. Methods to detect hypoxia-induced ischemic tolerance in the brain. Methods Enzymol 381: 399-416, 2004
29. Bernhardt WM, Warnecke C, Willam C, Tanaka T, Wies-ener MS, and Eckardt KU. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol 435: 221-245, 2007
30. Berra E, Benizri E, Ginouves A, Volmat V, Roux D, and Pouyssegur J. HIF prolyl-hydroxylase 2 is the key oxygen sensor setting low steady-state levels of HIF-1alpha in normoxia. EMBO J 22: 4082-4090, 2003
31. Bharath S, Hsu M, Kaur D, Rajagopalan S, and Andersen JK. Glutathione, iron and Parkinson's disease. Biochem Pharmacol 64: 1037-1048, 2002
32. Bianchi L, Tacchini L, and Cairo G. HIF-1-mediated activation of transferrin receptor gene transcription by iron chelation. Nucleic Acids Res 27: 4223-4227, 1999
33. Birkmayer W, Riederer P, Ambrozi L, and Youdim MBH. Implications of combined treatment with "Madopar" and L-deprenil in Parkinson's disease: a long-term study. Lancet 1: 439-443, 1977
34. Bolognin S, Drago D, Messori L, and Zatta P. Chelation therapy for neurodegenerative diseases. Med Res Rev 29: 547-570, 2009
35. Braak H and Del Tredici K. Poor and protracted myelina-tion as a contributory factor to neurodegenerative disorders. Neurobiol Aging 25: 19-23, 2004
36. Bruick RK. Oxygen sensing in the hypoxic response pathway: regulation of the hypoxia-inducible transcription factor. Genes Dev 17: 2614-2623, 2003
37. Brun A and Englund E. A white matter disorder in dementia of the Alzheimer type: a pathoanatomical study. Ann Neurol 19: 253-262, 1986
38. Bullock R. Future directions in the treatment of Alzheimer's disease. Expert Opin Invest Drugs 13: 303-314, 2004
39. Bush AI. The metallobiology of Alzheimer's disease. Trends Neurosci 26: 207-214, 2003
40. Bush AI. Drug development based on the metals hypothesis of Alzheimer's disease. J Alzheimers Dis 15: 223-240, 2008
41. Cahoon L. The curious case of clioquinol. Nat Med 15: 356-359, 2009
42. Carmeliet P and Storkebaum E. Vascular and neuronal effects of VEGF in the nervous system: implications for neurological disorders. Semin Cell Dev Biol 13: 39-53, 2002
43. Carrillo MC, Kitani K, Kanai S, Sato Y, Miyasaka K, and Ivy GO. (-)Deprenyl increases activities of superoxide dis-mutase and catalase in certain brain regions in old male mice. Life Sci 54: 975-981, 1994
44. Carrillo MC, Minami C, Kitani K, Maruyama W, Ohashi K, Yamamoto T, Naoi M, Kanai S, and Youdim MBH. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67: 577-585, 2000
45. Castellani RJ, Honda K, Zhu X, Cash AD, Nunomura A, Perry G, and Smith MA. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res Rev 3: 319-326, 2004
46. Castellani RJ, Moreira PI, Liu G, Dobson J, Perry G, Smith MA, and Zhu X. Iron: the redox-active center of oxidative stress in Alzheimer disease. Neurochem Res 32: 1640-1645, 2007
47. Chan DA, Kawahara TL, Sutphin PD, Chang HY, Chi JT, and Giaccia AJ. Tumor vasculature is regulated by PHD2 mediated angiogenesis and bone marrow-derived cell recruitment. Cancer Cell 15: 527-538, 2009
48. Chavez JC and LaManna JC. Hypoxia-inducible factor-1alpha accumulation in the rat brain in response to hypoxia and ischemia is attenuated during aging. Adv Exp Med Biol 510: 337-341, 2003
49. Cheah JH, Kim SF, Hester LD, Clancy KW, Patterson SE 3rd, Papadopoulos V, and Snyder SH. NMDA receptor-nitric oxide transmission mediates neuronal iron homeo-stasis via the GTPase Dexras1. Neuron 51: 431-440, 2006
50. Chen C, Yu R, Owuor ED, and Kong AN. Activation of antioxidant-response element (ARE), mitogen-activated protein kinases (MAPKs) and caspases by major green tea polyphenol components during cell survival and death. Arch Pharm Res 23: 605-612, 2000
51. Chen JJ and Ly AV. Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm 63: 915-928, 2006.
52. Cherny RA, Atwood CS, Xilinas ME, Gray DN, Jones WD, McLean CA, Barnham KJ, Volitakis I, Fraser FW, Kim Y, Huang X, Goldstein LE, Moir RD, Lim JT, Beyreuther K, Zheng H, Tanzi RE, Masters CL, and Bush AI. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease trans-genic mice. Neuron 30: 665-676, 2001
53. Cherny RA, Legg JT, McLean CA, Fairlie DP, Huang X, Atwood CS, Beyreuther K, Tanzi RE, Masters CL, and Bush AI. Aqueous dissolution of Alzheimer's disease Abeta amyloid deposits by biometal depletion. J Biol Chem 274: 23223-23228, 1999
54. Choi YT, Jung CH, Lee SR, Bae JH, Baek WK, Suh MH, Park J, Park CW, and Suh SI. The green tea polyphenol (-)-epigallocatechin gallate attenuates beta-amyloid-induced neurotoxicity in cultured hippocampal neurons. Life Sci 70: 603-614, 2001
55. Chu K, Jung KH, Kim SJ, Lee ST, Kim J, Park HK, Song EC, Kim SU, Kim M, Lee SK, and Roh JK. Transplantation of human neural stem cells protect against ischemia in a preventive mode via hypoxia-inducible factor-1alpha stabilization in the host brain. Brain Res 1207: 182-192, 2008
56. Cohen G. Oxidative stress, mitochondrial respiration, and Parkinson's disease. Ann N Y Acad Sci 899: 112-120, 2000
57. Connor JR and Lee SY. HFE mutations and Alzheimer's disease. J Alzheimers Dis 10: 267-276, 2006
58. Connor JR and Menzies SL. Cellular management of iron in the brain. J Neurol Sci 134(suppl): 33-44, 1995
59. Connor JR, Menzies SL, St Martin SM, and Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. J Neurosci Res 31: 75-83, 1992
60. Cozzolino M, Ferri A, and Carri MT. Amyotrophic lateral sclerosis: from current developments in the laboratory to clinical implications. Antioxid Redox Signal 10: 405-443, 2008
61. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W, and Andrews DF. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet 337: 1304-1328, 1991
62. Crichton RR and Pierre JL. Old iron, young copper: from Mars to Venus. Biometals 14: 99-112, 2001
63. Cronin S, Berger S, Ding J, Schymick JC, Washecka N, Hernandez DG, Greenway MJ, Bradley DG, Traynor BJ, and Hardiman O. A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum Mol Genet 17: 768-774, 2008
64. Crow JP, Calingasan NY, Chen J, Hill JL, and Beal MF. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 58: 258-265, 2005
65. Cummins EP, Berra E, Comerford KM, Ginouves A, Fitzgerald KT, Seeballuck F, Godson C, Nielsen JE, Moynagh P, Pouyssegur J, and Taylor CT. Prolyl hydroxylase-1 negatively regulates IkappaB kinase-beta, giving insight into hypoxia-induced NFkappaB activity. Proc Natl Acad Sci USA 103: 18154-18159, 2006
66. Czyzyk-Krzeska MF, Furnari BA, Lawson EE, and Millhorn DE. Hypoxia increases rate of transcription and stability of tyrosine hydroxylase mRNA in pheochromocytoma (PC12) cells. J Biol Chem 269: 760-764, 1994
67. Dai Q, Borenstein AR, Wu Y, Jackson JC, and Larson EB. Fruit and vegetable juices and Alzheimer's disease: the Kame Project. Am J Med 119: 751-759, 2006
68. Danzeisen R, Achsel T, Bederke U, Cozzolino M, Crosio C, Ferri A, Frenzel M, Gralla EB, Huber L, Ludolph A, Nencini M, Rotilio G, Valentine JS, and Carri MT. Superoxide dis-mutase 1 modulates expression of transferrin receptor. J Biol Inorg Chem 11: 489-498, 2006
69. Dedeoglu A, Cormier K, Payton S, Tseitlin KA, Kremsky JN, Lai L, Li X, Moir RD, Tanzi RE, Bush AI, Kowall NW, Rogers JT, and Huang X. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer's amyloi-dogenesis. Exp Gerontol 39: 1641-1649, 2004
70. Del Bo R, Ghezzi S, Scarpini E, Bresolin N, and Comi GP. VEGF genetic variability is associated with increased risk of developing Alzheimer's disease. J Neurol Sci 283: 66-68, 2009
71. Demougeot C, Van Hoecke M, Bertrand N, Prigent-Tessier A, Mossiat C, Beley A, and Marie C. Cytoprotective efficacy and mechanisms of the liposoluble iron chelator 2,2'-dipyridyl in the rat photothrombotic ischemic stroke model. J Pharmacol Exp Ther 311: 1080-1087, 2004
72. Dirnagl U, Simon RP, and Hallenbeck JM. Ischemic tolerance and endogenous neuroprotection. Trends Neurosci 26: 248-254, 2003
73. Ebadi M, Sharma S, Shavali S, and El Refaey H. Neuro-protective actions of selegiline. J Neurosci Res 67: 285-289, 2002
74. Ehrnhoefer DE, Duennwald M, Markovic P, Wacker JL, Engemann S, Roark M, Legleiter J, Marsh JL, Thompson LM, Lindquist S, Muchowski PJ, and Wanker EE. Green tea (-)-epigallocatechin-gallate modulates early events in hun-tingtin misfolding and reduces toxicity in Huntington's disease models. Hum Mol Genet 15: 2743-2751, 2006
75. Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O'Rourke J, Mole DR, Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N, Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW, Schofield CJ, and Ratcliffe PJ. C. elegans EGL-9 and mammalian ho-mologs define a family of dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107: 43-54, 2001
76. Fahey JW and Kensler TW. Role of dietary supplements= nutraceuticals in chemoprevention through induction of cytoprotective enzymes. Chem Res Toxicol 20: 572-576, 2007
77. Fandrey J. Oxygen-dependent and tissue-specific regulation of erythropoietin gene expression. Am J Physiol Regul Integr Comp Physiol 286: R977-R988, 2004
78. Faucheux BA, Bonnet AM, Agid Y, and Hirsch EC. Blood vessels change in the mesencephalon of patients with Parkinson's disease. Lancet 353: 981-982, 1999
79. Ferriero DM. Protecting neurons. Epilepsia 46(suppl 7): 45-51, 2005
80. Flugel D, Gorlach A, Michiels C, and Kietzmann T. Gly-cogen synthase kinase 3 phosphorylates hypoxia-inducible factor 1alpha and mediates its destabilization in a VHL-independent manner. Mol Cell Biol 27: 3253-3265, 2007
81. Fowler CJ, Wiberg A, Oreland L, Marcusson J, and Win-blad B. The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transmission 49: 1-20, 1980
82. Fowler JS, Logan J, Wang GJ, Volkow ND, Zhu W, Fran-ceschi D, Pappas N, Ferrieri R, Shea C, Garza V, Xu Y, MacGregor RR, Schlyer D, Gatley SJ, Ding YS, and Alexoff D. PET imaging of monoamine oxidase B in peripheral organs in humans. J Nucl Med 43: 1331-1338, 2002
83. Fraisl P, Aragones J, and Carmeliet P. Inhibition of oxygen sensors as a therapeutic strategy for ischaemic and inflammatory disease. Nat Rev Drug Discov 8: 139-152, 2009
84. Frede S, Stockmann C, Freitag P, and Fandrey J. Bacterial lipopolysaccharide induces HIF-1 activation in human monocytes via p44=42 MAPK and NF-kappaB. Biochem J 396: 517-527, 2006
85. Freret T, Valable S, Chazalviel L, Saulnier R, Mackenzie ET, Petit E, Bernaudin M, Boulouard M, and Schumann-Bard P. Delayed administration of deferoxamine reduces brain damage and promotes functional recovery after transient focal cerebral ischemia in the rat. Eur J Neurosci 23: 1757-1765, 2006
86. Fridovich I. Superoxide dismutases. Annu Rev Biochem 44: 147-159, 1975
87. Fukui H and Moraes CT. The mitochondrial impairment, oxidative stress and neurodegeneration connection: reality or just an attractive hypothesis? Trends Neurosci 31: 251-256, 2008
88. Gal S, Fridkin M, Amit T, Zheng H, and Youdim MB. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease. J Neural Transm Suppl: 447-456, 2006
89. Gal S, Zheng H, Fridkin M, and Youdim MB. Novel multifunctional neuroprotective iron chelator-monoamine oxi-dase inhibitor drugs for neurodegenerative diseases: in vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J Neuro-chem 95: 79-88, 2005 (Pubitemid 41384427)
90. Gal S, Zheng H, Fridkin M, and Youdim MB. Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox Res 2009 (DOI 10.1007=s12640-009-9070-9079)
91. Gassen M and Youdim MB. The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders. Pharmacol Toxicol 80: 159-166, 1997
92. Genc S, Koroglu TF, and Genc K. Erythropoietin and the nervous system. Brain Res 1000: 19-31, 2004
93. Genc S, Koroglu TF, and Genc K. Erythropoietin as a novel neuroprotectant. Restor Neurol Neurosci 22: 105-119, 2004
94. Gerlach M, Double KL, Youdim MB, and Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transmission suppl: 133-142, 2006
95. Gerlach M, Double KL, Youdim MBH, and Riederer P. Strategies for the protection of dopaminergic neurons against neurotoxicity. Neurotoxicol Res suppl 2: 99-114, 2000
96. Gidday JM, Fitzgibbons JC, Shah AR, and Park TS. Neu-roprotection from ischemic brain injury by hypoxic preconditioning in the neonatal rat. Neurosci Lett 168: 221-224, 1994
97. Gorres KL, Pua KH, and Raines RT. Stringency of the 2-His-1-Asp active-site motif in prolyl 4-hydroxylase. PLoS One 4: e7635, 2009
98. Gotz ME, Double K, Gerlach M, Youdim MB, and Riederer P. The relevance of iron in the pathogenesis of Parkinson's disease. Ann N Y Acad Sci 1012: 193-208, 2004
99. Gotz ME, Kunig G, Riederer P, and Youdim MB. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63: 37-122, 1994
100. Grunblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amar-iglo N, Rechavi G, Li J, Ravid R, Roggendorf W, Riederer P, and Youdim MB. Gene expression profiling of parkinso-nian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxida-tive stress regulated proteins, cell adhesion=cellular matrix and vesicle trafficking genes. J Neural Transm 111: 1543-1573, 2004
101. Grundke-Iqbal I, Fleming J, Tung YC, Lassmann H, Iqbal K, and Joshi JG. Ferritin is a component of the neuritic (senile) plaque in Alzheimer dementia. Acta Neuropathol 81: 105-110, 1990
102. Guo Q, Zhao B, Li M, Shen S, and Xin W. Studies on protective mechanisms of four components of green tea polyphenols against lipid peroxidation in synaptosomes. Biochim Biophys Acta 1304: 210-222, 1996
103. Guo S, Bragina O, Xu Y, Cao Z, Chen H, Zhou B, Morgan M, Lin Y, Jiang BH, Liu KJ, and Shi H. Glucose up-regulates HIF-1 alpha expression in primary cortical neurons in response to hypoxia through maintaining cellular redox status. J Neurochem 105: 1849-1860, 2008
104. Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem 59: 1609-1623, 1992
105. Halliwell B. Role of free radicals in the neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 18: 685-716, 2001
106. Halliwell B. Oxidative stress and neurodegeneration: where are we now? J Neurochem 97: 1634-1658, 2006
107. Halliwell B. Are polyphenols antioxidants or pro-oxidants? What do we learn from cell culture and in vivo studies? Arch Biochem Biophys 476: 107-112, 2008
108. Hamrick SE, McQuillen PS, Jiang X, Mu D, Madan A, and Ferriero DM. A role for hypoxia-inducible factor-1alpha in desferoxamine neuroprotection. Neurosci Lett 379: 96-100, 2005
109. Han J, Cheng FC, Yang Z, and Dryhurst G. Inhibitors of mitochondrial respiration, iron (II), and hydroxyl radical evoke release and extracellular hydrolysis of glutathione in rat striatum and substantia nigra: potential implications to Parkinson's disease. J Neurochem 73: 1683-1695, 1999
110. Hanauske-Abel HM. Prolyl 4-hydroxylase, a target enzyme for drug development: design of suppressive agents and the in vitro effects of inhibitors and proinhibitors. J Hepatol 13(suppl 3): S8-S15; discussion S16, 1991
111. Hanson ES, Rawlins ML, and Leibold EA. Oxygen and iron regulation of iron regulatory protein 2. J Biol Chem 278: 40337-40342, 2003
112. Harten SK, Ashcroft M, and Maxwell PH. Prolyl hydrox-ylase domain inhibitors: a route to HIF activation and neuroprotection. Antioxid Redox Signal 12: 459-480, 2010
113. Hegde ML, Bharathi P, Suram A, Venugopal C, Jagan-nathan R, Poddar P, Srinivas P, Sambamurti K, Rao KJ, Scancar J, Messori L, Zecca L, and Zatta P. Challenges associated with metal chelation therapy in Alzheimer's disease. J Alzheimers Dis 17: 457-468, 2009
114. Hellwig-Burgel T, Stiehl DP, Wagner AE, Metzen E, and Jelkmann W. Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. J Interferon Cytokine Res 25: 297-310, 2005
115. Hewitson KS, McNeill LA, and Schofield CJ. Modulating the hypoxia-inducible factor signaling pathway: applications from cardiovascular disease to cancer. Curr Pharm Des 10: 821-833, 2004
116. Hewitson KS and Schofield CJ. The HIF pathway as a therapeutic target. Drug Disc Today 9: 704-711, 2004
117. Hidalgo C, Carrasco MA, Munoz P, and Nunez MT. A role for reactive oxygen=nitrogen species and iron on neuronal synaptic plasticity. Antioxid Redox Signal 9: 245-255, 2007
118. Hider RC, Ma Y, Molina-Holgado F, Gaeta A, and Roy S. Iron chelation as a potential therapy for neurodegenerative disease. Biochem Soc Trans 36: 1304-1308, 2008
119. Higdon JV and Frei B. Tea catechins and polyphenols: health effects, metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 43: 89-143, 2003
120. Hirsch EC. Biochemistry of Parkinson's disease with special reference to the dopaminergic systems. Mol Neurobiol 9: 135-142, 1994
121. Hirsila M, Koivunen P, Xu L, Seeley T, Kivirikko KI, and Myllyharju J. Effect of desferrioxamine and metals on the hydroxylases in the oxygen sensing pathway. FASEB J 19: 1308-1310, 2005
122. Honda K, Smith MA, Zhu X, Baus D, Merrick WC, Tar-takoff AM, Hattier T, Harris PL, Siedlak SL, Fujioka H, Liu Q, Moreira PI, Miller FP, Nunomura A, Shimohama S, and Perry G. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J Biol Chem 280: 20978-20986, 2005
123. House E, Collingwood J, Khan A, Korchazkina O, Berthon G, and Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chela-tion therapy in Alzheimer's disease. J Alzheimers Dis 6: 291-301, 2004
124. Hur E, Chang KY, Lee E, Lee SK, and Park H. Mitogen-activated protein kinase kinase inhibitor PD98059 blocks the trans-activation but not the stabilization or DNA binding ability of hypoxia-inducible factor-1alpha. Mol Pharmacol 59: 1216-1224, 2001
125. Ibrahim NO, Hahn T, Franke C, Stiehl DP, Wirthner R, Wenger RH, and Katschinski DM. Induction of the hypoxia-inducible factor system by low levels of heat shock protein 90 inhibitors. Cancer Res 65: 11094-11100, 2005
126. Iliopoulos O, Levy AP, Jiang C, Kaelin WG Jr, and Goldberg MA. Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein. Proc Natl Acad Sci USA 93: 10595-10599, 1996
127. Imon Y, Yamaguchi S, Yamamura Y, Tsuji S, Kajima T, Ito K, and Nakamura S. Low intensity areas observed on T2-weighted magnetic resonance imaging of the cerebral cortex in various neurological diseases. J Neurol Sci 134(suppl): 27-32, 1995
128. Ishige K, Schubert D, and Sagara Y. Flavonoids protect neuronal cells from oxidative stress by three distinct mechanisms. Free Radic Biol Med 30: 433-446, 2001
129. 2-regulated prolyl hydroxylation. Science 292: 468-472, 2001
130. Jellinger K, Linert L, Kienzl E, Herlinger E, and Youdim MBH. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transmission Suppl 46: 297-314, 1995
131. Jellinger KA. Post mortem studies in Parkinson's disease: is it possible to detect brain areas for specific symptoms? J Neural Transmission Suppl: 1-29, 1991
132. Jellinger KA. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging 14: 115-140, 1999
133. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol Scand Suppl 136: 6-15, 1991
134. Jenner P. Oxidative mechanisms in nigral cell death in Parkinson's disease. Mov Disord 13: 24-34, 1998
135. Jenner P and Olanow CW. Oxidative stress and the path-ogenesis of Parkinson's disease. Neurology 47: S161-S170, 1996
136. Jenner P and Olanow CW. Understanding cell death in Parkinson's disease. Ann Neurol 44: S72-S84, 1998 (Pubitemid 28423832)
137. Jeon H, Kim H, Choi D, Kim D, Park SY, Kim YJ, Kim YM, and Jung Y. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothe-lial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol Pharmacol 71: 1676-1684, 2007
138. Jeong JW, Bae MK, Ahn MY, Kim SH, Sohn TK, Bae MH, Yoo MA, Song EJ, Lee KJ, and Kim KW. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetyla-tion. Cell 111: 709-720, 2002
139. Jeong SY, Rathore KI, Schulz K, Ponka P, Arosio P, and David S. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J Neurosci 29: 610-619, 2009
140. Jiang BH, Jiang G, Zheng JZ, Lu Z, Hunter T, and Vogt PK. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12: 3633-3639, 2001
141. John DC and Bulleid NJ. Intracellular dissociation and reassembly of prolyl 4-hydroxylase: the alpha-subunits associated with the immunoglobulin-heavy-chain binding protein (BiP) allowing reassembly with the beta-subunit. Biochem J 317: 659-665, 1996
142. Jones NM, Kardashyan L, Callaway JK, Lee EM, and Beart PM. Long-term functional and protective actions of preconditioning with hypoxia, cobalt chloride, and desfer-rioxamine against hypoxic-ischemic injury in neonatal rats. Pediatr Res 63: 620-624, 2008
143. Joseph JA, Shukitt-Hale B, and Casadesus G. Reversing the deleterious effects of aging on neuronal communication and behavior: beneficial properties of fruit polyphenolic compounds. Am J Clin Nutr 81: 313S-316S, 2005
144. Joseph JA, Shukitt-Hale B, Casadesus G, and Fisher D. Oxidative stress and inflammation in brain aging: nutritional considerations. Neurochem Res 30: 927-935, 2005
145. Kaelin WG. Proline hydroxylation and gene expression. Annu Rev Biochem 74: 115-128, 2005
146. Kalfon L, Youdim MB, and Mandel SA. Green tea poly-phenol (-)-epigallocatechin-3-gallate promotes the rapid protein kinase C-and proteasome-mediated degradation of Bad: implications for neuroprotection. J Neurochem 100: 992-1002, 2007
147. Kasarskis EJ, Tandon L, Lovell MA, and Ehmann WD. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser mi-croprobe mass spectroscopy: a preliminary study. J Neurol Sci 130: 203-208, 1995
148. Kato H, Amersi F, Buelow R, Melinek J, Coito AJ, Ke B, Busuttil RW, and Kupiec-Weglinski JW. Heme oxygenase-1 overexpression protects rat livers from ischemia= reperfusion injury with extended cold preservation. Am J Transplant 1: 121-128, 2001
149. Katschinski DM, Le L, Schindler SG, Thomas T, Voss AK, and Wenger RH. Interaction of the PAS B domain with HSP90 accelerates hypoxia-inducible factor-1alpha stabilization. Cell Physiol Biochem 14: 351-360, 2004
150. Kaur D, Yantiri F, Rajagopalan S, Kumar J, Mo JQ, Boon-plueang R, Viswanath V, Jacobs R, Yang L, Beal MF, Di-Monte D, Volitaskis I, Ellerby L, Cherny RA, Bush AI, and Andersen JK. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 37: 899-909., 2003
151. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann N Y Acad Sci 119: 758-768, 1964
152. Kim JW, Tchernyshyov I, Semenza GL, and Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hyp-oxia. Cell Metab 3: 177-185, 2006
153. Kitani K, Kanai S, Ivy GO, and Carrillo MC. Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy. Mech Ageing Dev 111: 211-221, 1999
154. Kobayashi S, Harris VA, and Welsh FA. Spreading depression induces tolerance of cortical neurons to ischemia in rat brain. J Cereb Blood Flow Metab 15: 721-727, 1995
155. Koh SH, Kim SH, Kwon H, Kim JG, Kim JH, Yang KH, Kim J, Kim SU, Yu HJ, Do BR, Kim KS, and Jung HK. Phos-phatidylinositol-3 kinase=Akt and GSK-3 mediated cyto-protective effect of epigallocatechin gallate on oxidative stress-injured neuronal-differentiated N18D3 cells. Neuro-toxicology 25: 793-802, 2004
156. Koh SH, Lee SM, Kim HY, Lee KY, Lee YJ, Kim HT, Kim J, Kim MH, Hwang MS, Song C, Yang KW, Lee KW, Kim SH, and Kim OH. The effect of epigallocatechin gallate on suppressing disease progression of ALS model mice. Neurosci Lett 395: 103-107, 2006
157. Kriz J, Nguyen MD, and Julien JP. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 10: 268-278, 2002
158. Kumamoto M, Sonda T, Nagayama K, and Tabata M. Effects of pH and metal ions on antioxidative activities of catechins. Biosci Biotechnol Biochem 65: 126-132, 2001
159. Kupershmidt L, Weinreb O, Amit T, Mandel S, Carri MT, and Youdim MB. Neuroprotective and neuritogenic activities of novel multimodal iron-chelating drugs in motor-neuron-like NSC-34 cells and transgenic mouse model of amyotrophic lateral sclerosis. FASEB J 23: 3766-3779, 2009
160. Lai CT, Zuo DM, and Yu PH. Is brain superoxide dismutase activity
161. Lambrechts D, Storkebaum E, Morimoto M, Del-Favero J, Desmet F, Marklund SL, Wyns S, Thijs V, Andersson J, van Marion I, Al-Chalabi A, Bornes S, Musson R, Hansen V, Beckman L, Adolfsson R, Pall HS, Prats H, Vermeire S, Rutgeerts P, Katayama S, Awata T, Leigh N, Lang-Lazdunski L, Dewerchin M, Shaw C, Moons L, Vlietinck R, Morrison KE, Robberecht W, Van Broeckhoven C, Collen D, Andersen PM, and Carmeliet P. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat Genet 34: 383-394, 2003
162. Lan J and Jiang DH. Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice. J Neural Transmission (Budapest) 104: 469-481, 1997
163. Lan J and Jiang DH. Excessive iron accumulation in the brain: a possible potential risk of neurodegeneration in Parkinson's disease. J Neural Transmission 104: 649-660, 1997
164. Lannfelt L, Blennow K, Zetterberg H, Batsman S, Ames D, Harrison J, Masters CL, Targum S, Bush AI, Murdoch R, Wilson J, and Ritchie CW. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol 7: 779-786, 2008
165. LaVaute T, Smith S, Cooperman S, Iwai K, Land W, Meyron-Holtz E, Drake SK, Miller G, Abu-Asab M, Tsokos M, Switzer R, 3rd, Grinberg A, Love P, Tresser N, and Rouault TA. Targeted deletion of the gene encoding iron regulatory protein-2 causes misregulation of iron metabolism and neurodegenerative disease in mice. Nature Genet 27: 209-214, 2001
166. Lazarovici P, Gazit A, Staniszewska I, Marcinkiewicz C, and Lelkes PI. Nerve growth factor (NGF) promotes an-giogenesis in the quail chorioallantoic membrane. Endo-thelium 13: 51-59, 2006
167. Lee DW and Andersen JK. Role of HIF-1 in iron regulation: potential therapeutic strategy for neurodegenerative disorders. Curr Mol Med 6: 883-893, 2006
168. Lee DW, Rajagopalan S, Siddiq A, Gwiazda R, Yang L, Beal MF, Ratan RR, and Andersen JK. Inhibition of prolyl hydroxylase protects against MPTP-induced neurotoxic-ity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson's disease. J Biol Chem 284: 29065-29076, 2009
169. Lee KA, Roth RA, and LaPres JJ. Hypoxia, drug therapy and toxicity. Pharmacol Ther 113: 229-246, 2007
170. Lee KH, Choi E, Chun YS, Kim MS, and Park JW. Differential responses of two degradation domains of HIF-1alpha to hypoxia and iron deficiency. Biochimie 88: 163-169, 2006
171. Lee PJ, Jiang BH, Chin BY, Iyer NV, Alam J, Semenza GL, and Choi AM. Hypoxia-inducible factor-1 mediates tran-scriptional activation of the heme oxygenase-1 gene in response to hypoxia. J Biol Chem 272: 5375-5381, 1997
172. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV, Freeman RS, Carter BD, Kaelin WG Jr, and Schlisio S. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 8: 155-167, 2005
173. Lee S, Suh S, and Kim S. Protective effects of the green tea polyphenol (-)-epigallocatechin gallate against hippocam-pal neuronal damage after transient global ischemia in gerbils. Neurosci Lett 287: 191-194, 2000
174. Lees AJ, Shaw KM, Kohout LJ, Stern GM, Elsworth JD, Sandler M, and Youdim MBH. Deprenyl in Parkinson's disease. Lancet 2: 791-795, 1977
175. Lesage S and Brice A. Parkinson's disease: from monogenic forms to genetic susceptibility factors. Hum Mol Genet 18: R48-R59, 2009
176. Levites Y, Amit T, Mandel S, and Youdim MBH. Neuro-protection and neurorescue against Abeta toxicity and PKC-dependent release of nonamyloidogenic soluble precursor protein by green tea polyphenol (-)-epigallocatechin-3- gallate. FASEB J 17: 952-954, 2003
177. Levites Y, Amit T, Youdim MB, and Mandel S. Involvement of protein kinase C activation and cell survival=cell cycle genes in green tea polyphenol (-)-epigallocatechin 3-gallate neuroprotective action. J Biol Chem 277: 30574-30580, 2002
178. Levites Y, Weinreb O, Maor G, Youdim MBH, and Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate prevents N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopaminergic neurodegeneration. J Neurochem 78: 1073-1082, 2001
179. Li R, Peng N, Du F, Li XP, and Le WD. Epigallocatechin gallate protects dopaminergic neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- induced neurotoxicity by inhibiting microglial cell activation. Nan Fang Yi Ke Da Xue Xue Bao 26: 376-380, 2006
180. Li YX, Ding SJ, Xiao L, Guo W, and Zhan Q. Desferox-amine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci Bull 24: 89-95, 2008
181. Li Z, Ya K, Xiao-Mei W, Lei Y, Yang L, and Ming QZ. Ginkgolides protect PC12 cells against hypoxia-induced injury by p42=p44 MAPK pathway-dependent upregula-tion of HIF-1alpha expression and HIF-1DNA-binding activity. J Cell Biochem 103: 564-575, 2008
182. Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, and Youdim MBH. Dopamine, 6-hydroxydopamine, iron, and dioxygen: their mutual interactions and possible implication in the development of Parkinson's disease. Bio-chim Biophys Acta 1316: 160-168, 1996
183. Liu J, Ginis I, Spatz M, and Hallenbeck JM. Hypoxic preconditioning protects cultured neurons against hypoxic stress via TNF-alpha and ceramide. Am J Physiol Cell Physiol 278: C144-C153, 2000
184. Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, and Gong CX. Decreased glucose transporters correlate to abnormal hyper-phosphorylation of tau in Alzheimer disease. FEBS Lett 582: 359-364, 2008
185. Long LH, Clement MV, and Halliwell B. Artifacts in cell culture: rapid generation of hydrogen peroxide on addition of (-)-epigallocatechin, (-)-epigallocatechin gallate, (\+)-catechin, and quercetin to commonly used cell culture media. Biochem Biophys Res Commun 273: 50-53, 2000
186. Lorincz MT. Clinical implications of Parkinson's disease genetics. Semin Neurol 26: 492-498, 2006
187. Lovell MA, Robertson JD, Teesdale WJ, Campbell JL, and Markesbery WR. Copper, iron and zinc in Alzheimer's disease senile plaques. J Neurol Sci 158: 47-52, 1998
188. Madsen E and Gitlin JD. Copper and iron disorders of the brain. Annu Rev Neurosci 30: 317-337, 2007
189. Magyar K, Palfi M, Jenei V, and Szoko E. Deprenyl: from chemical synthesis to neuroprotection. J Neural Transmission Suppl 71: 143-156, 2006
190. Maharaj H, Sukhdev Maharaj D, Scheepers M, Mokokong R, and Daya S. l-DOPA administration enhances 6-hydro-xydopamine generation. Brain Res 1063: 180-186, 2005
191. Maher P, Akaishi T, and Abe K. Flavonoid fisetin promotes ERK-dependent long-term potentiation and enhances memory. Proc Natl Acad Sci USA 103: 16568-16573, 2006
192. Majamaa K, Gunzler V, Hanauske-Abel HM, Myllyla R, and Kivirikko KI. Partial identity of the 2-oxoglutarate and ascorbate binding sites of prolyl 4-hydroxylase. J Biol Chem 261: 7819-7823, 1986
193. Mandel SA, Avramovich-Tirosh Y, Reznichenko L, Zheng H, Weinreb O, Amit T, and Youdim MB. Multifunctional activities of green tea catechins in neuroprotection: modulation of cell survival genes, iron-dependent oxidative stress and PKC signaling pathway. Neurosignals 14: 46-60, 2005
194. Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, and Naoi M. Neuroprotection by propargylamines in Parkinson's disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol Teratol 24: 675-682, 2002
195. Masson N, Willam C, Maxwell PH, Pugh CW, and Ratcliffe PJ. Independent function of two destruction domains in hypoxia-inducible factor-alpha chains activated by prolyl hydroxylation. EMBO J 20: 5197-5206, 2001
196. Mastrogiannaki M, Matak P, Keith B, Simon MC, Vaulont S, and Peyssonnaux C. HIF-2alpha, but not HIF-1alpha, promotes iron absorption in mice. J Clin Invest 119: 1159-1166, 2009
197. Maxwell P and Salnikow K. HIF-1: an oxygen and metal responsive transcription factor. Cancer Biol Ther 3: 29-35, 2004
198. Maxwell PH. Hypoxia-inducible factor as a physiological regulator. Exp Physiol 90: 791-797, 2005
199. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, Wykoff CC, Pugh CW, Maher ER, and Ratcliffe PJ. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent prote-olysis. Nature 399: 271-275, 1999
200. McDonough MA, Li V, Flashman E, Chowdhury R, Mohr C, Lienard BM, Zondlo J, Oldham NJ, Clifton IJ, Lewis J, McNeill LA, Kurzeja RJ, Hewitson KS, Yang E, Jordan S, Syed RS, and Schofield CJ. Cellular oxygen sensing: crystal structure of hypoxia-inducible factor prolyl hydroxylase (PHD2). Proc Natl Acad Sci USA 103: 9814-9819, 2006
201. McNaught KS and Jenner P. Proteasomal function is impaired in substantia nigra in Parkinson's disease. Neurosci Lett 297: 191-194, 2001
202. Mendel GA. Studies on iron absorption, I: the relationships between the rate of erythropoiesis, hypoxia and iron absorption. Blood 18: 727-736, 1961
203. Mikhaylova O, Ignacak ML, Barankiewicz TJ, Harbaugh SV, Yi Y, Maxwell PH, Schneider M, Van Geyte K, Car-meliet P, Revelo MP, Wyder M, Greis KD, Meller J, and Czyzyk-Krzeska MF. The von Hippel-Lindau tumor suppressor protein and Egl-9-type proline hydroxylases regulate the large subunit of RNA polymerase II in response to oxidative stress. Mol Cell Biol 28: 2701-2717, 2008
204. Miller RG, Mitchell JD, Lyon M, and Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)=motor neuron disease (MND). Cochrane Database Syst Rev CD001447, 2007
205. Mishra RR, Adhikary G, Simonson MS, Cherniack NS, and Prabhakar NR. Role of c-fos in hypoxia-induced AP-1 cis-element activity and tyrosine hydroxylase gene expression. Brain Res Mol Brain Res 59: 74-83, 1998
206. Missero C, Calautti E, Eckner R, Chin J, Tsai LH, Livingston DM, and Dotto GP. Involvement of the cell-cycle inhibitor Cip1=WAF1 and the E1A-associated p300 protein in terminal differentiation. Proc Natl Acad Sci USA 92: 5451-5455, 1995
207. Mizuno Y, Amari M, Takatama M, Aizawa H, Mihara B, and Okamoto K. Transferrin localizes in Bunina bodies in amyotrophic lateral sclerosis. Acta Neuropathol 112: 597-603, 2006
208. Molina-Holgado F, Hider RC, Gaeta A, Williams R, and Francis P. Metals ions and neurodegeneration. Biometals 20: 639-654, 2007
209. Moos T, Rosengren Nielsen T, Skjorringe T, and Morgan EH. Iron trafficking inside the brain. J Neurochem 103: 1730-1740, 2007
210. Moreira PI, Honda K, Liu Q, Santos MS, Oliveira CR, Aliev G, Nunomura A, Zhu X, Smith MA, and Perry G. Oxidative stress: the old enemy in Alzheimer's disease pathophysi-ology. Curr Alzheimer Res 2: 403-408, 2005 (Pubitemid 41277754)
211. Morse LJ, Payton SM, Cuny GD, and Rogers JT. FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J Mol Neurosci 24: 129-136, 2004
212. Mu D, Chang YS, Vexler ZS, and Ferriero DM. Hypoxia-inducible factor 1alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp Neu-rol 195: 407-415, 2005
213. Nangaku M, Izuhara Y, Takizawa S, Yamashita T, Fujii-Kuriyama Y, Ohneda O, Yamamoto M, van Ypersele de Strihou C, Hirayama N, and Miyata T. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia. Arterioscler Thromb Vasc Biol 27: 2548-2554, 2007
214. Napolitano M, Centonze D, Calce A, Picconi B, Spiezia S, Gulino A, Bernardi G, and Calabresi P. Experimental par-kinsonism modulates multiple genes involved in the trans-duction of dopaminergic signals in the striatum. Neurobiol Dis 10: 387-395, 2002
215. Nguyen MV, Pouvreau S, El Hajjaji FZ, Denavit-Saubie M, and Pequignot JM. Desferrioxamine enhances hypoxic ventilatory response and induces tyrosine hydroxylase gene expression in the rat brainstem in vivo. J Neurosci Res 85: 1119-1125, 2007
216. Nie G, Jin C, Cao Y, Shen S, and Zhao B. Distinct effects of tea catechins on 6-hydroxydopamine-induced apoptosis in PC12 cells. Arch Biochem Biophys 397: 84-90, 2002
217. 2-responsive sequences on the tyrosine hy-droxylase gene. J Biol Chem 270: 23774-23779, 1995
218. Nygren I, Larsson A, Johansson A, and Askmark H. VEGF is increased in serum but not in spinal cord from patients with amyotrophic lateral sclerosis. Neuroreport 13: 2199-2201, 2002
219. M. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology 189: 843-846, 1993
220. Obregon DF, Rezai-Zadeh K, Bai Y, Sun N, Hou H, Ehrhart J, Zeng J, Mori T, Arendash GW, Shytle D, Town T, and Tan J. ADAM10 activation is required for green tea (-)-epigallocatechin-3-gallate-induced alpha-secretase cleavage of amyloid precursor protein. J Biol Chem 281: 16419-16427, 2006
221. Ogunshola OO and Antoniou X. Contribution of hypoxia to Alzheimer's disease: is HIF-1alpha a mediator of neurodegeneration? Cell Mol Life Sci 66: 3555-3563, 2009
222. Olanow CW. Oxidation reactions in Parkinson's disease. Neurology 40(suppl): 32-37; discussion 37-39, 1990
223. Olanow CW. Early therapy for Parkinson's disease. Eur Neurol 32: 30-35, 1992
224. Olanow CW, Hauser RA, Jankovic J, Langston W, Lang A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E, and Rascol O. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 23: 2194-2201, 2008
225. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, Langston W, Melamed E, Poewe W, Stocchi F, and Tolosa E. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361: 1268-1278, 2009
226. Olanow CW, Stern MB, and Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 72: S1-S136, 2009
227. Palmer C, Menzies SL, Roberts RL, Pavlick G, and Connor JR. Changes in iron histochemistry after hypoxic-ischemic brain injury in the neonatal rat. J Neurosci Res 56: 60-71, 1999
228. Palmer C, Roberts RL, and Bero C. Deferoxamine post-treatment reduces ischemic brain injury in neonatal rats. Stroke 25: 1039-1045, 1994
229. Park SS, Bae I, and Lee YJ. Flavonoids-induced accumulation of hypoxia-inducible factor (HIF)-1alpha=2alpha is mediated through chelation of iron. J Cell Biochem 103: 1989-1998, 2008
230. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med. 321: 176-183, 1989
231. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease. Arch Neurol 59: 1937-1993, 2002
232. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61: 561-566, 2004
233. Payton S, Cahill CM, Randall JD, Gullans SR, and Rogers JT. Drug discovery targeted to the Alzheimer's APP mRNA 5'-untranslated region: the action of paroxetine and di-mercaptopropanol. J Mol Neurosci 20: 267-275, 2003
234. Peng Z, Ren P, Kang Z, Du J, Lian Q, Liu Y, Zhang JH, and Sun X. Up-regulated HIF-1alpha is involved in the hypoxic tolerance induced by hyperbaric oxygen preconditioning. Brain Res 1212: 71-78, 2008
235. Perron NR and Brumaghim JL. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. Cell Biochem Biophys 53: 75-100, 2009
236. Perron NR, Hodges JN, Jenkins M, and Brumaghim JL. Predicting how polyphenol antioxidants prevent DNA damage by binding to iron. Inorg Chem 47: 6153-6161, 2008
237. Perry TL, Godin DV, and Hansen S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33: 305-310, 1982
238. Peyssonnaux C, Zinkernagel AS, Schuepbach RA, Rankin E, Vaulont S, Haase VH, Nizet V, and Johnson RS. Regulation of iron homeostasis by the hypoxia-inducible transcription factors (HIFs). J Clin Invest 117: 1926-1932, 2007
239. Pinero DJ, Hu J, and Connor JR. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer's diseased brains. Cell Mol Biol (Noisy-Le-Grand) 46: 761-776, 2000
240. 2 protect HepG2 cells against serum deprivation-and t-BHP-induced apoptosis: a possible anti-apoptotic role for HIF-1. Exp Cell Res 295: 340-349, 2004
241. Prass K, Ruscher K, Karsch M, Isaev N, Megow D, Priller J, Scharff A, Dirnagl U, and Meisel A. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cereb Blood Flow Metab 22: 520-525, 2002
242. Pratico D and Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer's disease. Am J Med 109: 577-585, 2000
243. Przedborski S. Programmed cell death in amyotrophic lateral sclerosis: a mechanism of pathogenic and therapeutic importance. Neurologist 10: 1-7, 2004
244. Rabie T, Marti HH. Brain protection by erythropoietin: a manifold task. Physiology (Bethesda) 23: 263-274, 2008
245. Ran R, Xu H, Lu A, Bernaudin M, and Sharp FR. Hypoxia preconditioning in the brain. Dev Neurosci 27: 87-92, 2005
246. Ratan RR, Siddiq A, Aminova L, Langley B, McConoughey S, Karpisheva K, Lee HH, Carmichael T, Kornblum H, Coppola G, Geschwind DH, Hoke A, Smirnova N, Rink C, Roy S, Sen C, Beattie MS, Hart RP, Grumet M, Sun D, Freeman RS, Semenza GL, and Gazaryan I. Small molecule activation of adaptive gene expression: tilorone or its analogs are novel potent activators of hypoxia inducible factor-1 that provide prophylaxis against stroke and spinal cord injury. Ann N Y Acad Sci 1147: 383-394, 2008
247. Rezai-Zadeh K, Arendash GW, Hou H, Fernandez F, Jensen M, Runfeldt M, Shytle RD, and Tan J. Green tea epigallocatechin-3-gallate (EGCG) reduces beta-amyloid mediated cognitive impairment and modulates tau pathology in Alzheimer transgenic mice. Brain Res 1214: 177-187, 2008
248. Rezai-Zadeh K, Shytle D, Sun N, Mori T, Hou H, Jeanniton D, Ehrhart J, Townsend K, Zeng J, Morgan D, Hardy J, Town T, and Tan J. Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci 25: 8807-8814, 2005
249. Reznichenko L, Amit T, Youdim MB, and Mandel S. Green tea polyphenol (-)-epigallocatechin-3-gallate induces neu-rorescue of long-term serum-deprived PC12 cells and promotes neurite outgrowth. J Neurochem 93: 1157-1167, 2005
250. Reznichenko L, Amit T, Zheng H, Avramovich-Tirosh Y, Youdim MB, Weinreb O, and Mandel S. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: implications for iron chelation in Alzheimer's disease. J Neurochem 97: 527-536, 2006
251. Rice-Evans C. Flavonoid antioxidants. Curr Med Chem 8: 797-807, 2001
252. Richardson DR. Novel chelators for central nervous system disorders that involve alterations in the metabolism of iron and other metal ions. Ann N Y Acad Sci 1012: 326-341, 2004
253. Riederer P, Dirr A, Goetz M, Sofic E, Jellinger K, and Youdim MBH. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol 32(suppl): S101-S104, 1992
254. Riederer P, Sofic E, Rausch WD, Schmidt B, Reynolds GP, Jellinger K, and Youdim MBH. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52: 515-520, 1989
255. Ritchie CW, Bush AI, Mackinnon A, Macfarlane S, Mast-wyk M, MacGregor L, Kiers L, Cherny R, Li QX, Tammer A, Carrington D, Mavros C, Volitakis I, Xilinas M, Ames D, Davis S, Beyreuther K, Tanzi RE, and Masters CL. Metal-protein attenuation with iodochlorhydroxyquin (clioqui-nol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol 60: 1685-1691, 2003
256. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, and Ward P. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci USA 89: 10016-10020, 1992
257. Rogers JT, Bush AI, Cho HH, Smith DH, Thomson AM, Friedlich AL, Lahiri DK, Leedman PJ, Huang X, and Cahill CM. Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: riboregulation against neural oxidative damage in Alzheimer's disease. Biochem Soc Trans 36: 1282-1287, 2008
258. Rogers JT and Lahiri DK. Metal and inflammatory targets for Alzheimer's disease. Curr Drug Targets 5: 535-551, 2004
259. Rogers JT, Randall JD, Cahill CM, Eder PS, Huang X, Gunshin H, Leiter L, McPhee J, Sarang SS, Utsuki T, Greig NH, Lahiri DK, Tanzi RE, Bush AI, Giordano T, and Gullans SR. An iron-responsive element type II in the 5'-untranslated region of the Alzheimer's amyloid precursor protein transcript. J Biol Chem 277: 45518-45528, 2002
260. Rogers JT, Randall JD, Eder PS, Huang X, Bush AI, Tanzi RE, Venti A, Payton SM, Giordano T, Nagano S, Cahill CM, Moir R, Lahiri DK, Greig N, Sarang SS, and Gullans SR. Alzheimer's disease drug discovery targeted to the APP mRNA 5'untranslated region. J Mol Neurosci 19: 77-82, 2002
261. Rohrbach S, Simm A, Pregla R, Franke C, and Katschinski DM. Age-dependent increase of prolyl-4-hydroxylase domain (PHD) 3 expression in human and mouse heart. Bio-gerontology 6: 165-171, 2005
262. Rolfs A, Kvietikova I, Gassmann M, and Wenger RH. Oxygen-regulated transferrin expression is mediated by hypoxia-inducible factor-1. J Biol Chem 272: 20055-20062, 1997
263. Roskams AJ and Connor JR. Iron, transferrin, and ferritin in the rat brain during development and aging. J Neurochem 63: 709-716, 1994
264. Rottkamp CA, Raina AK, Zhu X, Gaier E, Bush AI, Atwood CS, Chevion M, Perry G, and Smith MA. Redox-active iron mediates amyloid-beta toxicity. Free Radic Biol Med 30: 447-450, 2001
265. Rouault TA and Cooperman S. Brain iron metabolism. Semin Pediatr Neurol 13: 142-148, 2006
266. Roy A, Volgin DV, Baby SM, Mokashi A, Kubin L, and Lahiri S. Activation of HIF-1alpha mRNA by hypoxia and iron chelator in isolated rat carotid body. Neurosci Lett 363: 229-232, 2004
267. Sabbagh A and Youdim MBH. Selective inhibition of monoamine oxidase type B by propargyl-containing drugs. Israel J Med Sci 14: 1097, 1978
268. Sagi Y, Mandel S, Amit T, and Youdim MB. Activation of tyrosine kinase receptor signaling pathway by rasagi-line facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 25: 35-44, 2007 (Pubitemid 44765215)
269. Salnikow K, Su W, Blagosklonny MV, and Costa M. Carcinogenic metals induce hypoxia-inducible factor-stimulated transcription by reactive oxygen species-independent mechanism. Cancer Res 60: 3375-3378, 2000
270. Salvatore MF, Fisher B, Surgener SP, Gerhardt GA, and Rouault T. Neurochemical investigations of dopamine neu-ronal systems in iron-regulatory protein 2 (IRP-2) knockout mice. Brain Res Mol Brain Res 139: 341-347, 2005
271. Sarco DP, Becker J, Palmer C, Sheldon RA, and Ferriero DM. The neuroprotective effect of deferoxamine in the hypoxic-ischemic immature mouse brain. Neurosci Lett 282: 113-116, 2000
272. Saura J, Luque JM, Cesura AM, Da Prada M, Chan-Palay V, Huber G, Loffler J, and Richards JG. Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioau-tography. Neuroscience 62: 15-30, 1994.
273. Sayre LM, Perry G, Harris PL, Liu Y, Schubert KA, and Smith MA. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: a central role for bound transition metals. J Neurochem 74: 270-279, 2000
274. Sayre LM, Smith MA, and Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr Med Chem 8: 721-738, 2001
275. Schapira AH and Olanow CW. Drug selection and timing of initiation of treatment in early Parkinson's disease. Ann Neurol 64(suppl 2): S47-S55, 2008
276. Schipper HM. Heme oxygenase expression in human central nervous system disorders. Free Radic Biol Med 37: 1995-2011, 2004
277. Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer's disease: interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem Res 30: 895-908, 2005
278. Schnell PO, Ignacak ML, Bauer AL, Striet JB, Paulding WR, and Czyzyk-Krzeska MF. Regulation of tyrosine hydroxy-lase promoter activity by the von Hippel-Lindau tumor suppressor protein and hypoxia-inducible transcription factors. J Neurochem 85: 483-491, 2003
279. Schofield CJ and Ratcliffe PJ. Oxygen sensing by HIF hy-droxylases. Nat Rev Mol Cell Biol 5: 343-354, 2004
280. Schulz JB, Lindenau J, Seyfried J, and Dichgans J. Glu-tathione, oxidative stress and neurodegeneration. Eur J Biochem 267: 4904-4911, 2000
281. Selkoe DJ and Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol 43: 545-584, 2003
282. Semenza GL. Hypoxia-inducible factor 1: oxygen homeo-stasis and disease pathophysiology. Trends Mol Med 7: 345-350, 2001
283. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 3: 721-732, 2003
284. Semenza GL, Roth PH, Fang HM, and Wang GL. Tran-scriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J Biol Chem 269: 23757-23763, 1994
285. Semenza GL and Wang GL. A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation. Mol Cell Biol 12: 5447-5454, 1992
286. Sen CK and Packer L. Antioxidant and redox regulation of gene transcription. FASEB J 10: 709-720, 1996
287. Sharp FR, Bergeron M, and Bernaudin M. Hypoxia-inducible factor in brain. Adv Exp Med Biol 502: 273-591, 2001
288. Shimohama S, Tanino H, Kawakami N, Okamura N, Kodama H, Yamaguchi T, Hayakawa T, Nunomura A, Chiba S, Perry G, Smith MA, and Fujimoto S. Activation of NADPH oxidase in Alzheimer's disease brains. Biochem Biophys Res Commun 273: 5-9, 2000
289. Shoulson I. An interim report of the effect of selegiline (L-deprenyl) on the progression of disability in early Parkinson's disease: the Parkinson Study Group. Eur Neurol 32(suppl 1): 46-53, 1992
290. Siddiq A, Aminova LR, and Ratan RR. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: center stage in the battle against hypoxia, metabolic compromise and oxida-tive stress. Neurochem Res 32: 931-946, 2007
291. Siddiq A, Aminova LR, and Ratan RR. Prolyl 4-hydroxy-lase activity-responsive transcription factors: from hydrox-ylation to gene expression and neuroprotection. Front Biosci 13: 2875-2887, 2008
292. Siddiq A, Aminova LR, Troy CM, Suh K, Messer Z, Semenza GL, and Ratan RR. Selective inhibition of hyp-oxia-inducible factor (HIF) prolyl-hydroxylase 1 mediates neuroprotection against normoxic oxidative death via HIF-and CREB-independent pathways. J Neurosci 29: 8828-8838, 2009
293. Siddiq A, Ayoub IA, Chavez JC, Aminova L, Shah S, La-Manna JC, Patton SM, Connor JR, Cherny RA, Volitakis I, Bush AI, Langsetmo I, Seeley T, Gunzler V, and Ratan RR. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition: a target for neuroprotection in the central nervous system. J Biol Chem 280: 41732-41743, 2005
294. Singh VP, Saluja AK, Bhagat L, van Acker GJ, Song AM, Soltoff SP, Cantley LC, and Steer ML. Phosphatidylinositol 3-kinase-dependent activation of trypsinogen modulates the severity of acute pancreatitis. J Clin Invest 108: 1387-1395, 2001
295. Sivakumar V, Lu J, Ling EA, and Kaur C. Vascular endo-thelial growth factor and nitric oxide production in response to hypoxia in the choroid plexus in neonatal brain. Brain Pathol 18: 71-85, 2008
296. Smith DG, Cappai R, and Barnham KJ. The redox chemistry of the Alzheimer's disease amyloid beta peptide. Bio-chim Biophys Acta 1768: 1976-1990, 2007
297. Smith MA, Harris PL, Sayre LM, and Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci USA 94: 9866-9868, 1997
298. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, Tabaton M, and Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxi-dative stress. J Neurochem 70: 2212-2215, 1998
299. Smith MA, Rottkamp CA, Nunomura A, Raina AK, and Perry G. Oxidative stress in Alzheimer's disease. Biochim Biophys Acta 1502: 139-144, 2000
300. Smith MA, Wehr K, Harris PL, Siedlak SL, Connor JR, and Perry G. Abnormal localization of iron regulatory protein in Alzheimer's disease. Brain Res 788: 232-326, 1998
301. Smith SR, Cooperman S, Lavaute T, Tresser N, Ghosh M, Meyron-Holtz E, Land W, Ollivierre H, Jortner B, Switzer R 3rd, Messing A, and Rouault TA. Severity of neurodegen-eration correlates with compromise of iron metabolism in mice with iron regulatory protein deficiencies. Ann N Y Acad Sci 1012: 65-83, 2004
302. Snowdon DA. Healthy aging and dementia: findings from the Nun Study. Ann Intern Med 139: 450-454, 2003
303. Soucek T, Cumming R, Dargusch R, Maher P, and Schubert D. The regulation of glucose metabolism by HIF-1 mediates a neuroprotective response to amyloid beta peptide. Neuron 39: 43-56, 2003
304. Sterling J, Veinberg A, Lerner D, Goldenberg W, Levy R, Youdim M, and Finberg J. (R)(\+)-N-propargyl-1-aminoindan (rasagiline) and derivatives: highly selective and potent inhibitors of monoamine oxidase B. J Neural Transmission Suppl 52: 301-305, 1998
305. Stockmann C and Fandrey J. Hypoxia-induced erythropoi-etin production: a paradigm for oxygen-regulated gene expression. Clin Exp Pharmacol Physiol 33: 968-979, 2006
306. Streifler M and Rabey MJ. Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients. J Neural Transmission Suppl 19: 265-272, 1983
307. Sun AY and Chen YM. Oxidative stress and neurodegen-erative disorders. J Biomed Sci 5: 401-414, 1998
308. Sutedja NA, Sinke RJ, Van Vught PW, Van der Linden MW, Wokke JH, Van Duijn CM, Njajou OT, Van der Schouw YT, Veldink JH, and Van den Berg LH. The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Arch Neurol 64: 63-67, 2007
309. Sutherland BA, Rahman RM, and Appleton I. Mechanisms of action of green tea catechins, with a focus on ischemia-induced neurodegeneration. J Nutr Biochem 17: 291-306, 2006
310. Sutherland BA, Shaw OM, Clarkson AN, Jackson DN, Sammut IA, and Appleton I. Neuroprotective effects of (-)-epigallocatechin gallate following hypoxia-ischemia-induced brain damage: novel mechanisms of action. FASEB J 19: 258-260, 2005
311. Takeda A, Perry G, Abraham NG, Dwyer BE, Kutty RK, Laitinen JT, Petersen RB, and Smith MA. Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J Biol Chem 275: 5395-5399, 2000
312. Tatton WG, Chalmers-Redman RM, Ju WJ, Mammen M, Carlile GW, Pong AW, and Tatton NA. Propargylamines induce antiapoptotic new protein synthesis in serum-and nerve growth factor (NGF)-withdrawn, NGF-differentiated PC-12 cells. J Pharmacol Exp Ther 301: 753-764, 2002
313. Taylor CT and Pouyssegur J. Oxygen, hypoxia, and stress. Ann N Y Acad Sci 1113: 87-94, 2007
314. Thomas R and Kim MH. Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells. Biochem Biophys Res Commun 334: 543-548, 2005
315. Tian B, Sun Z, Xu Z, and Hua Y. Chemiluminescence analysis of the prooxidant and antioxidant effects of epi-gallocatechin-3-gallate. Asia Pac J Clin Nutr 16(suppl 1): 153-157, 2007
316. Treiber C, Simons A, Strauss M, Hafner M, Cappai R, Bayer TA, and Multhaup G. Clioquinol mediates copper uptake and counteracts copper efflux activities of the amyloid precursor protein of Alzheimer's disease. J Biol Chem 279: 51958-51964, 2004
317. Triantafyllou A, Liakos P, Tsakalof A, Chachami G, Paraskeva E, Molyvdas PA, Georgatsou E, Simos G, and Bonanou S. The flavonoid quercetin induces hypoxiainducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. Free Radic Res 41: 342-356, 2007
318. Triantafyllou A, Mylonis I, Simos G, Bonanou S, and Tsakalof A. Flavonoids induce HIF-1alpha but impair its nuclear accumulation and activity. Free Radic Biol Med 44: 657-670, 2008
319. Tsolaki M, Kokarida K, Iakovidou V, Stilopoulos E, Meimaris J, and Kazis A. Extrapyramidal symptoms and signs in Alzheimer's disease: prevalence and correlation with the first symptom. Am J Alzheimers Dis Other Dement 16: 268-278, 2001
320. Turner BJ and Talbot K. Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 85: 94-134, 2008
321. Urushitani M, Ezzi SA, and Julien JP. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 104: 2495-2500, 2007
322. Valdmanis PN, Daoud H, Dion PA, and Rouleau GA. Recent advances in the genetics of amyotrophic lateral sclerosis. Curr Neurol Neurosci Rep 9: 198-205, 2009
323. van Acker SA, van den Berg DJ, Tromp MN, Griffioen DH, van Bennekom WP, van der Vijgh WJ, and Bast A. Structural aspects of antioxidant activity of flavonoids. Free Radic Biol Med 20: 331-342, 1996
324. Veijola J, Pihlajaniemi T, and Kivirikko KI. Co-expression of the alpha subunit of human prolyl 4-hydroxylase with BiP polypeptide in insect cells leads to the formation of soluble and insoluble complexes: soluble alpha-subunit-BiP complexes have no prolyl 4-hydroxylase activity. Biochem J 315: 613-618, 1996
325. Vexler ZS and Ferriero DM. Molecular and biochemical mechanisms of perinatal brain injury. Semin Neonatol 6: 99-108, 2001
326. Waibel S, Reuter A, Malessa S, Blaugrund E, and Ludolph AC. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J Neurol 251: 1080-1084, 2004
327. Wang GL and Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 270: 1230-1237, 1995
328. Wang XS, Lee S, Simmons Z, Boyer P, Scott K, Liu W, and Connor J. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J Neurol Sci 227: 27-33, 2004
329. Warnecke C, Griethe W, Weidemann A, Jurgensen JS, Willam C, Bachmann S, Ivashchenko Y, Wagner I, Frei U, Wiesener M, and Eckardt KU. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J 17: 1186-1188, 2003
330. Warshakoon NC, Wu S, Boyer A, Kawamoto R, Sheville J, Renock S, Xu K, Pokross M, Zhou S, Winter C, Walter R, Mekel M, and Evdokimov AG. Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1alpha prolyl hydroxylase inhibitors. Bioorg Med Chem Lett 16: 5517-5522, 2006
331. Wei IH, Wu YC, Wen CY, and Shieh JY. Green tea poly-phenol (-)-epigallocatechin gallate attenuates the neuronal NADPH-d=nNOS expression in the nodose ganglion of acute hypoxic rats. Brain Res 999: 73-80, 2004
332. Weinreb O, Amit T, and Youdim MB. A novel approach of proteomics and transcriptomics to study the mechanism of action of the antioxidant-iron chelator green tea polyphenol (-)-epigallocatechin-3-gallate. Free Radic Biol Med 43: 546-556, 2007
333. Weinreb O, Amit T, and Youdim MB. The application of proteomics for studying the neurorescue activity of the polyphenol (-)-epigallocatechin-3- gallate. Arch Biochem Biophys 476: 152-160, 2008
334. Weinreb O, Bar-Am O, Amit T, Chillag-Talmor O, and Youdim MBH. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J 18: 1471-1473, 2004
335. Weinreb O, Bar-Am O, Amit T, Drigues N, Sagi Y, and Youdim MB. The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity. Chem Biol Interact 175: 318-326, 2008
336. Weinreb O, Mandel S, Amit T, and Youdim MBH. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases. J Nutri Biochem 15: 506-516, 2004
337. Weinreb O, Mandel S, and Youdim MBH. cDNA gene expression profile homology of antioxidants and their an-tiapoptotic and proapoptotic activities in human neuro-blastoma cells. FASEB J 17: 935-937, 2003
338. Weinstock M, Kirschbaum-Slager N, Lazarovici P, Bejar C, Shoami E, and MBH Y. Cell culture and in vivo neuro-protective effects of novel cholinesterase-MAO inhibitors derived from rasagiline as potential anti-Alzheimer drugs. Ann N Y Acad Sci 939: 148-161, 2000
339. White AR, Du T, Laughton KM, Volitakis I, Sharples RA, Xilinas ME, Hoke DE, Holsinger RM, Evin G, Cherny RA, Hill AF, Barnham KJ, Li QX, Bush AI, and Masters CL. Degradation of the Alzheimer disease amyloid beta-peptide by metal-dependent up-regulation of metallopro-tease activity. J Biol Chem 281: 17670-17680, 2006
340. Whitnall M and Richardson DR. Iron: a new target for pharmacological intervention in neurodegenerative diseases. Semin Pediatr Neurol 13: 186-197, 2006
341. Wiesener MS, Jurgensen JS, Rosenberger C, Scholze CK, Horstrup JH, Warnecke C, Mandriota S, Bechmann I, Frei UA, Pugh CW, Ratcliffe PJ, Bachmann S, Maxwell PH, and Eckardt KU. Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J 17: 271-273, 2003
342. Wilson WJ and Poellinger L. The dietary flavonoid quer-cetin modulates HIF-1 alpha activity in endothelial cells. Biochem Biophys Res Commun 293: 446-450, 2002
343. Witten L, Sager T, Thirstrup K, Johansen JL, Larsen DB, Montezinho LP, and Mork A. HIF prolyl hydroxylase inhibition augments dopamine release in the rat brain in vivo. J Neurosci Res 87: 1686-1694, 2009
344. Xiao XQ, Lee NT, Carlier PR, Pang Y, and Han YF. Bis(7)-tacrine, a promising anti-Alzheimer's agent, reduces hydrogen peroxide-induced injury in rat pheochromocytoma cells: comparison with tacrine. Neurosci Lett 290: 197-200, 2000
345. Yogev-Falach M, Amit T, Bar-AM O, and Youdim MBH. The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J 17: 2325-2327, 2003
346. Yogev-Falach M, Bar-Am O, Amit T, Weinreb O, and Youdim MB. A multifunctional, neuroprotective drug, la-dostigil (TV3326), regulates holo-APP translation and processing. FASEB J 20: 2177-2179, 2006
347. Youdim MB. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti-Alzheimer drugs ladostigil and m30. Curr Alzheimer Res 3: 541-550, 2006
348. Youdim MB. Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotox Res 14: 45-56, 2008
349. Youdim MB and Buccafusco JJ. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol Sci 26: 27-35, 2005
350. Youdim MB, Fridkin M, and Zheng H. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. J Neural Transmission 111: 1455-1471, 2004
351. Youdim MB, Stephenson G, and Ben Shachar D. Ironing iron out in Parkinson's disease and other neurode-generative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Ann N Y Acad Sci 1012: 306-325, 2004
352. Zaman K, Ryu H, Hall D, O'Donovan K, Lin KI, Miller MP, Marquis JC, Baraban JM, Semenza GL, and Ratan RR. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1=CREB and increased expression of glycolytic enzymes, p21(waf1=cip1), and erythropoietin. J Neurosci 19: 9821-9830, 1999
353. Zatta P, Drago D, Bolognin S, and Sensi SL. Alzheimer's disease, metal ions and metal homeostatic therapy. Trends Pharmacol Sci 30: 346-355, 2009
354. Zecca L, M.B.H. Y, Riederer P, Connor JR, and Crichton RR. Iron, brain ageing and neurodegenerative disorders. Nat Rev Neurosci 5: 863-873, 2004
355. Zecca L, Stroppolo A, Gatti A, Tampellini D, Toscani M, Gallorini M, Giaveri G, Arosio P, Santambrogio P, Fariello RG, Karatekin E, Kleinman MH, Turro N, Hornykiewicz O, and Zucca FA. The role of iron and copper molecules in the neuronal vulnerability of locus coeruleus and substantia nigra during aging. Proc Natl Acad Sci USA 101: 9843-19838, 2004
356. Zhang B, Tanaka J, Yang L, Yang L, Sakanaka M, Hata R, Maeda N, and Mitsuda N. Protective effect of vitamin E against focal brain ischemia and neuronal death through induction of target genes of hypoxia-inducible factor-1. Neuroscience 126: 433-440, 2004
357. Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, and Youdim MB. Novel multifunctional neu-roprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95: 68-78, 2005
358. Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB, and Fridkin M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases. Bioorg Med Chem 13: 773-783, 2005
359. Zheng H, Youdim MB, Weiner LM, and Fridkin M. Novel potential neuroprotective agents with both iron chelating and amino acid-based derivatives targeting central ner-voussystem neurons. Biochem Pharmacol 70: 1642-1652,2005
360. Zhong H, Chiles K, Feldser D, Laughner E, Hanrahan C, Georgescu MM, Simons JW, and Semenza GL. Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor=phosphatidylinositol 3-kinase= PTEN=AKT=FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res 60: 1541-1545, 2000
361. Zhou YD, Kim YP, Li XC, Baerson SR, Agarwal AK, Hodges TW, Ferreira D, and Nagle DG. Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts. J Nat Prod 67: 2063-2069, 2004
362. Zhu W, Xie W, Pan T, Jankovic J, Li J, Youdim MB, and Le W. Comparison of neuroprotective and neurorestorative capabilities of rasagiline and selegiline against lactacystin-induced nigrostriatal dopaminergic degeneration. J Neu-rochem 105: 1970-1978, 2008
363. Zhu W, Xie W, Pan T, Xu P, Fridkin M, Zheng H, Jankovic J, Youdim MB, and Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J 21: 3835-3844, 2007
364. Ziello JE, Jovin IS, and Huang Y. Hypoxia-inducible factor (HIF)-1 regulatory pathway and its potential for therapeutic intervention in malignancy and ischemia. Yale J Biol Med 80: 51-60, 2007
365. Znamensky V, Akama KT, McEwen BS, and Milner TA. Estrogen levels regulate the subcellular distribution of phosphorylated Akt in hippocampal CA1 dendrites. J Neurosci 23: 2340-2347, 2003.